These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 25930208)

  • 1. Global variation in clinical profile, management, and post-discharge outcomes among patients hospitalized for worsening chronic heart failure: findings from the ASTRONAUT trial.
    Greene SJ; Fonarow GC; Solomon SD; Subacius H; Maggioni AP; Böhm M; Lewis EF; Zannad F; Gheorghiade M;
    Eur J Heart Fail; 2015 Jun; 17(6):591-600. PubMed ID: 25930208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial.
    Greene SJ; Maggioni AP; Fonarow GC; Solomon SD; Böhm M; Kandra A; Prescott MF; Reimund B; Hua TA; Lesogor A; Zannad F; Gheorghiade M;
    Eur J Heart Fail; 2015 Jan; 17(1):98-108. PubMed ID: 25597870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program.
    Blair JE; Zannad F; Konstam MA; Cook T; Traver B; Burnett JC; Grinfeld L; Krasa H; Maggioni AP; Orlandi C; Swedberg K; Udelson JE; Zimmer C; Gheorghiade M;
    J Am Coll Cardiol; 2008 Nov; 52(20):1640-8. PubMed ID: 18992654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.
    Gheorghiade M; Böhm M; Greene SJ; Fonarow GC; Lewis EF; Zannad F; Solomon SD; Baschiera F; Botha J; Hua TA; Gimpelewicz CR; Jaumont X; Lesogor A; Maggioni AP;
    JAMA; 2013 Mar; 309(11):1125-35. PubMed ID: 23478743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
    Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M
    Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global variation in quality of care among patients hospitalized with acute heart failure in an international trial: findings from the acute study clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND-HF).
    Howlett JG; Ezekowitz JA; Podder M; Hernandez AF; Diaz R; Dickstein K; Dunlap ME; Corbalán R; Armstrong PW; Starling RC; O'Connor CM; Califf RM; Fonarow GC;
    Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):534-42. PubMed ID: 23899930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial.
    Maggioni AP; Greene SJ; Fonarow GC; Böhm M; Zannad F; Solomon SD; Lewis EF; Baschiera F; Hua TA; Gimpelewicz CR; Lesogor A; Gheorghiade M;
    Eur Heart J; 2013 Oct; 34(40):3117-27. PubMed ID: 23999456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS.
    Bhatt AS; Luo N; Solomon N; Pagidipati NJ; Ambrosio G; Green JB; McGuire DK; Standl E; Cornel JH; Halvorsen S; Lopes RD; White HD; Holman RR; Peterson ED; Mentz RJ;
    Am Heart J; 2019 Dec; 218():57-65. PubMed ID: 31707329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial.
    Ambrosy AP; Pang PS; Khan S; Konstam MA; Fonarow GC; Traver B; Maggioni AP; Cook T; Swedberg K; Burnett JC; Grinfeld L; Udelson JE; Zannad F; Gheorghiade M;
    Eur Heart J; 2013 Mar; 34(11):835-43. PubMed ID: 23293303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study.
    Tromp J; Bamadhaj S; Cleland JGF; Angermann CE; Dahlstrom U; Ouwerkerk W; Tay WT; Dickstein K; Ertl G; Hassanein M; Perrone SV; Ghadanfar M; Schweizer A; Obergfell A; Lam CSP; Filippatos G; Collins SP
    Lancet Glob Health; 2020 Mar; 8(3):e411-e422. PubMed ID: 32087174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial.
    Butler J; Subacius H; Vaduganathan M; Fonarow GC; Ambrosy AP; Konstam MA; Maggioni A; Mentz RJ; Swedberg K; Zannad F; Gheorghiade M;
    J Am Coll Cardiol; 2013 Feb; 61(5):571-9. PubMed ID: 23246389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial.
    Mentz RJ; Cotter G; Cleland JG; Stevens SR; Chiswell K; Davison BA; Teerlink JR; Metra M; Voors AA; Grinfeld L; Ruda M; Mareev V; Lotan C; Bloomfield DM; Fiuzat M; Givertz MM; Ponikowski P; Massie BM; O'Connor CM
    Eur J Heart Fail; 2014 Jun; 16(6):614-24. PubMed ID: 24771609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial.
    Greene SJ; Vaduganathan M; Wilcox JE; Harinstein ME; Maggioni AP; Subacius H; Zannad F; Konstam MA; Chioncel O; Yancy CW; Swedberg K; Butler J; Bonow RO; Gheorghiade M;
    JACC Heart Fail; 2013 Dec; 1(6):488-96. PubMed ID: 24622000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
    Greene SJ; Gheorghiade M; Vaduganathan M; Ambrosy AP; Mentz RJ; Subacius H; Maggioni AP; Nodari S; Konstam MA; Butler J; Filippatos G;
    Eur J Heart Fail; 2013 Dec; 15(12):1401-11. PubMed ID: 23845795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity).
    Wong CM; Hawkins NM; Jhund PS; MacDonald MR; Solomon SD; Granger CB; Yusuf S; Pfeffer MA; Swedberg K; Petrie MC; McMurray JJ
    J Am Coll Cardiol; 2013 Nov; 62(20):1845-54. PubMed ID: 23850914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial).
    Shah AN; Mentz RJ; Gheorghiade M; Kwasny MJ; Fought AJ; Zannad F; Swedberg K; Maggioni AP; Konstam MA
    Am J Cardiol; 2012 Dec; 110(12):1803-8. PubMed ID: 22999071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial).
    Metra M; Mentz RJ; Hernandez AF; Heizer GM; Armstrong PW; Clausell N; Corbalan R; Costanzo MR; Dickstein K; Dunlap ME; Ezekowitz JA; Howlett JG; Komajda M; Krum H; Lombardi C; Fonarow GC; McMurray JJ; Nieminen MS; Swedberg K; Voors AA; Starling RC; Teerlink JR; O'Connor CM
    Am J Cardiol; 2016 Jun; 117(11):1771-8. PubMed ID: 27108685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Geographic Region on the COMMANDER-HF Trial.
    Ferreira JP; Cleland JGF; Lam CSP; van Veldhuisen DJ; Byra WM; La Police DA; Anker SD; Mehra MR; Leroy C; Eschwege V; Toussaint-Hacquard M; Rossignol P; Greenberg B; Zannad F
    JACC Heart Fail; 2021 Mar; 9(3):201-211. PubMed ID: 33549557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials.
    Wong YW; Mentz RJ; Felker GM; Ezekowitz J; Pieper K; Heizer G; Hasselblad V; Metra M; O'Connor CM; Armstrong PW; Starling RC; Hernandez AF
    Eur J Heart Fail; 2016 Jun; 18(6):684-92. PubMed ID: 26817735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-II.
    Giugliano RP; Llevadot J; Wilcox RG; Gurfinkel EP; McCabe CH; Charlesworth A; Thompson SL; Antman EM; Braunwald E;
    Eur Heart J; 2001 Sep; 22(18):1702-15. PubMed ID: 11511120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.